Liposomal bupivacaine: a review of a new bupivacaine formulation

Praveen Chahar, Kenneth C Cummings 3rd, Praveen Chahar, Kenneth C Cummings 3rd

Abstract

Many attempts have been made to increase the duration of local anesthetic action. One avenue of investigation has focused on encapsulating local anesthetics within carrier molecules to increase their residence time at the site of action. This article aims to review the literature surrounding the recently approved formulation of bupivacaine, which consists of bupivacaine loaded in multivesicular liposomes. This preparation increases the duration of local anesthetic action by slow release from the liposome and delays the peak plasma concentration when compared to plain bupivacaine administration. Liposomal bupivacaine has been approved by the US Food and Drug Administration for local infiltration for pain relief after bunionectomy and hemorrhoidectomy. Studies have shown it to be an effective tool for postoperative pain relief with opioid sparing effects and it has also been found to have an acceptable adverse effect profile. Its kinetics are favorable even in patients with moderate hepatic impairment, and it has been found not to delay wound healing after orthopedic surgery. More studies are needed to establish its safety and efficacy for use via intrathecal, epidural, or perineural routes. In conclusion, liposomal bupivacaine is effective for treating postoperative pain when used via local infiltration when compared to placebo with a prolonged duration of action, predictable kinetics, and an acceptable side effect profile. However, more adequately powered trials are needed to establish its superiority over plain bupivacaine.

Keywords: efficacy; liposomal bupivacaine; pharmacodynamics; pharmacokinetics; postoperative pain; safety.

Figures

Figure 1
Figure 1
Scanning electron microscope image of DepoFoam® containing bupivacaine. Image supplied courtesy of Pacira Pharmaceuticals, Inc, 5 Sylvan Way, Parsippany, NJ 07054.
Figure 2
Figure 2
Cross-sectional diagram of DepoFoam containing bupivacaine. Image supplied courtesy of Pacira Pharmaceuticals, Inc, 5 Sylvan Way, Parsippany, NJ 07054.

References

    1. Acerbi A, Parisi D. The evolution of pain. In: Costa FA, Rocha LM, Costa E, Harvey I, Coutinho A, editors. Advances in Artificial Life; ECAL 2007: Proceedings of the 9th Annual Conference on Advances in Artificial Life; September 10–14, 2007; Lisbon, Portugal. Berlin: Springer; 2007. pp. 816–824.
    1. Loeser JD, Melzack R. Pain: an overview. Lancet. 1999;353(9164):1607–1069.
    1. Breivik H. Pain management. Baillieres Clin Anaesthesiol. 1994;8(4):775–795.
    1. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol. 2007;21(1):65–83.
    1. Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin Interv Aging. 2008;3(2):273–278.
    1. Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009;22(5):588–593.
    1. Dahl V, Raeder JC. Non-opioid postoperative analgesia. Acta Anaesthesiol Scand. 2000;44(10):1191–1203.
    1. Tuncer S, Aysolmaz G, Reisli R, Erol A, Yalçin N, Yosunkaya A. The effects of the administration of subfacial levobupivacaine infusion with the ON-Q pain pump system on postoperative analgesia and tramadol consumption in cesarean operations. Agri. 2010;22(2):73–78.
    1. Borgeat A, Ekatodramis G. Anaesthesia for shoulder surgery. Best Pract Res Clin Anaesthesiol. 2002;16(2):211–225.
    1. Osada R, Zukawa M, Seki E, Kimura T. Continuous peripheral nerve block in forearm for severe hand trauma. Hand Surg. 2011;16(3):239–244.
    1. Chelly JE, Delaunay L, Williams B, Borghi B. Outpatient lower extremity infusions. Best Pract Res Clin Anaesthesiol. 2002;16(2):311–320.
    1. Richman JM, Liu SS, Courpas G, et al. Does continuous peripheral nerve block provide superior pain control to opioids? A meta-analysis. Anesth Analg. 2006;102(1):248–257.
    1. Chelly JE, Ghisi D, Fanelli A. Continuous peripheral nerve blocks in acute pain management. Br J Anaesth. 2010;105(Suppl 1):i86–i96.
    1. Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res. 2002;41(5):392–406.
    1. New RRC. Influence of liposome characteristics on their properties and fate. In: Philippot JR, Schuber F, editors. Liposomes as Tools in Basic Research and Industry. Boca Raton: CRC Press; 1995. pp. 3–20.
    1. Mowat JJ, Mok MJ, MacLeod BA, Madden TD. Liposomal bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Anesthesiology. 1996;85(3):635–643.
    1. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm. 1989;46(8):1576–1587.
    1. Richard BM, Ott LR, Haan D, et al. The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs. Expert Opin Investig Drugs. 2011;20(10):1327–1341.
    1. Richard BM, Newton P, Ott LR, et al. The safety of EXPAREL® (bupivacaine liposome injectable suspension) administered by peripheral nerve block in rabbits and dogs. J Drug Deliv [Serial on the Internet] Jan, 2012. [Accessed July 2, 2012]. [cited July 2, 2012];962101:[10 p.].
    1. Dullenkopf A, Borgeat A. Local anesthetics. Differences and similarities in the “-cains”. Anaesthesist. 2003;52(4):329–340.
    1. Covino BG. Pharmacology of local anaesthetic agents. Br J Anaesth. 1986;58(7):701–716.
    1. Davidson EM, Barenholz Y, Cohen R, Haroutiunian S, Kagan L, Ginosar Y. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg. 2010;110(4):1018–1023.
    1. Langford RM, Chappell GM, Karrasch JA. A single administration of DepoBupivacaine (TM) intraoperatively results in prolonged detectable plasma bupivacaine and analgesia in patients undergoing inguinal hernia repair. Poster presented at: 62nd Annual Postgraduate Assembly of the New York State Society of Anesthesiologists; December 12–16, 2008; New York, NY.
    1. Gantenbein M, Attolini L, Bruguerolle B, et al. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000;28(4):383–385.
    1. Onel E, Warnott K, Lambert W, Patou G. Pharmacokinetics of depobupivacaine (EXPAREL™), a novel bupivacaine extended release liposomal injection, in volunteers with moderate hepatic impairment. Poster presented at: 112th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics; March 3–6, 2011; Dallas, TX.
    1. US Food and Drug Administration. FDA Label Approved on 10/28/2011 (PDF) for EXPAREL. US Silver Spring, MD: US Food and Drug Administration; [Accessed May 01, 2012]. Available from: .
    1. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54(12):1552–1559.
    1. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28(9):776–788.
    1. Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammoplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012;32(1):69–76.
    1. Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012 Jan 27; In press.
    1. Boogaerts JG, Lafont ND, Declercq AG, et al. Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: a first study. J Clin Anesth. 1994;6(4):315–320.
    1. AstraZeneca Canada. Bupivacaine Prescribing Information. Mississauga, ON: AstraZeneca Canada Inc; [Accessed April 28, 2012]. Available from: .
    1. Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet. 1979;4(4):241–278.
    1. Wolfe JW, Butterworth JF. Local anesthetic systemic toxicity: update on mechanisms and treatment. Curr Opin Anaesthesiol. 2011;24(5):561–566.
    1. Yang S, Abrahams MS, Hurn PD, Grafe MR, Kirsch JR. Local anesthetic Schwann cell toxicity is time and concentration dependent. Reg Anesth Pain Med. 2011;36(5):444–451.
    1. Zink W, Graf BM. Local anesthetic myotoxicity. Reg Anesth Pain Med. 2004;29(4):333–340.
    1. Gómez-Arnau JI, Yangüela J, González A, et al. Anaesthesia-related diplopia after cataract surgery. Br J Anaesth. 2003;90(2):189–193.
    1. Vlăduţiu C, Sevan S, Ciuică M. Diplopia through toxic myopathy after cataract surgery. Oftalmologia. 2008;52(4):77–82.
    1. Bergese SD, Onel E, Morren M, Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med. 2012;37(2):145–151.
    1. Naseem A, Harada T, Wang D, et al. Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers. J Clin Pharmacol. Epub November 4, 2011.
    1. Minkowitz HS, Onel E, Patronella CK, Smoot JD. A two-year observational study assessing the safety of DepoFoam bupivacaine after augmentation mammaplasty. Aesthet Surg J. 2012;32(2):186–193.
    1. Pinto LM, Pereira R, de Paula E, de Nucci G, Santana MH, Donato JL. Influence of liposomal local anesthetics on platelet aggregation in vitro. J Liposome Res. 2004;14(1–2):51–59.
    1. Pacira Pharmaceuticals Inc. Exparel (Bupivacaine Liposome Injectable Suspension) Product Monograph. Parsippany, NJ: Pacira Pharmaceuticals, Inc; [Accessed May 01, 2012]. Available from: .

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner